DOCSLIB.ORG

WR 70S 3.08: (Continued) C07K I4/95 (2006.01) (52) U.S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WR 70S 3.08: (Continued) C07K I4/95 (2006.01) (52) U.S USOO958.0471B2 (12) United States Patent (10) Patent No.: US 9,580,471 B2 Bai et al. (45) Date of Patent: Feb. 28, 2017 (54) PROCESS OF PREPARING GUANYLATE 7,041,786 B2 5/2006 Shailubhai et al. CYCLASE CAGONSTS 7.33 E. S. Seaallubha et al. 2006/0160989 A1* 7/2006 Kundu et al. ................. 530/330 (75) Inventors: R EN"S"S (S. 2009/0048175 A1 2/2009 Shailubhai et al. ............ 514f13 steps E" O hai 'S f 2010.0069306 A1 3/2010 Shailubhai et al. (US); Jun Jia, Shanghai (CN), Junfeng 2010/0093635 A1 4/2010 Shailubhai et al. Zhou, Shanghai (CN), Qiao Zhao, 2010, 0120694 A1 5/2010 Shailubhai et al. Shanghai (CN). Guoquing Zhang 2010/0152118 A1 6, 2010 Shailubhai et al. Shanghai (CN); Kunwar Shailubhai, 2010/0221329 A1 9, 2010 Shailubhai et al. Audubon, PA (US); Stephen Comiskey, Doylestown, PA (US); Rong Feng, FOREIGN PATENT DOCUMENTS Langhorne, PA (US) JP H5-508859. A 12/1993 (73) Assignee: SYNERGY PHARMACEUTICALS, sO 3.99, A 1 is: INC., New York, NY (US) WO WOO2/O78683 10, 2002 - WO WO-20081373.18 A1 11, 2008 (*) Notice: Subject to any disclaimer, the term of this WO WO2008,151257 12/2008 patent is extended or adjusted under 35 WO WO2009/149278 12/2009 U.S.C. 154(b) by 0 days. WO WO2009, 1492.79 12/2009 WO WO2010/0093.19 1, 2010 WO WO-2010O27405 A2 3, 2010 (21) Appl. No.: 14/001,638 WO WO2010/065751 6, 2010 WO WO2O11,069038 6, 2011 (22) PCT Filed: Mar. 1, 2012 WO WO2012f1 18972 9, 2012 (86). PCT No.: PCT/US2012/0272.87 OTHER PUBLICATIONS S 371 (c)(1), & 8 (2), (4) Date: Feb. 11, 2014 Currie et al., “Guanylin: An endogenous activator of intestinal guanylate cyclase.” Proc. Natl. Acad. Sci. USA 89:947-951 (1992). (87) PCT Pub. No.: WO2012/118972 Forte, "Guanylin regulatory peptides: structures, biological activi ties mediated by cyclic GMP and pathobiology.” Reg. Pept. 81:25 PCT Pub. Date: Sep. 7, 2012 39 (1999). O O Guba et al., “Guanylin Strongly Stimulates Rat Duodenal HCO (65) Prior Publication Data Secretion: Proposed Mechanism and Comparison With Other US 2014/O155575 A1 Jun. 5, 2014 Secretagogues.” Gastroenterology 1 11:1558-1568 (1996). • al-s Hamra et al., “Uroguanylin: Structure and activity of a second Related U.S. Application Data endogenous peptide that stimulates intestinal guanylate cyclase.” Proc. Natl. Acad. Sci. USA 90:10464-10468 (1993). (60) Provisional application No. 61/447,891, filed on Mar. Schulz et al., “Guanylyl Cyclase Is a Heat-Stable Enterotoxin 1, 2011. Receptor.” Cell 63:941-948 (1990). Joo et al., “Regulation of intestinal C1 and HCO, secretion by (51) Int. Cl. uroguanylin.” Am. J. Physiol. 274:G633-G644 (1998). WR 70s 3.08: (Continued) C07K I4/95 (2006.01) (52) U.S. Cl. Primary Examiner — Christina Bradley CPC .................. C07K 7/64 (2013.01); C07K 7/08 (74) Attorney, Agent, or Firm — Cynthia Kozakiewicz; (2013.01); C07K 14/195 (2013.01) Ivor Elrifi (58) Field of Classification Search CPC ...................................................... CO7K 1/O26 See application file for complete search history. (57) ABSTRACT (56) References Cited The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group U.S. PATENT DOCUMENTS consisting of SEQ ID NOs: 1-249 described herein. 4,107,158 A * 8/1978 Lefrancier .................... 530,328 5,322.931 A * 6/1994 Hubbs et al. ................. 530.333 5,977.302 A * 11/1999 Palmer et al. ................ 530/339 12 Claims, 3 Drawing Sheets US 9,580.471 B2 Page 2 (56) References Cited OTHER PUBLICATIONS Carpino et al., “Rapid, Continuous Solution-Phase Peptide Synthe sis: Application to Peptides of Pharmaceutical Interest'. Org. Proc. Res. Dev. (2003), 7 (1):28-37. European Application No. 12752488, Extended European Search Report dated Mar. 24, 2015. European Application No. 12752488, Partial European Search Report dated Nov. 19, 2014. PCT/US2012/027287. International Search Report mailed Oct. 23, 2012. PCT/US2012/027287. International Preliminary Report on Patent ability mailed. PCT/US2012/027287. Written Opinion mailed Oct. 23, 2012, 6 pageS. Fujino et al., “Syntheses and biological activities of analogs of luteinizing hormone releasing hormone (LH-RH).” Biochemical and Biophysical Research Communications (1972); 49(3): 698-705. Nyfeler, R., “Peptide synthesis via fragment condensation.” Peptide Synthesis Protocols (1995); 35:303-316. * cited by examiner U.S. Patent Feb. 28, 2017 Sheet 1 of 3 US 9,580,471 B2 V Y NN V N N CO C v g NN N s NN N CN 5. NN SS d O cy) cy) (WM) peulee 96 U.S. Patent Feb. 28, 2017 Sheet 2 of 3 US 9,580,471 B2 U.S. Patent Feb. 28, 2017 Sheet 3 of 3 US 9,580,471 B2 - US 9,580,471 B2 1. 2 PROCESS OF PREPARING GUANYLATE patches of diseased bowel, ulcerative colitis affects only the CYCLASE CAGONSTS innermost lining (mucosa) of the colon in a continuous manner. Depending on which portion of the gastrointestinal RELATED APPLICATIONS tract is involved, Crohn's disease may be referred to as illeitis, regional enteritis, colitis, etc. Crohn's disease and This application is a 35 U.S.C. S371 National Phase ulcerative colitis differ from spastic colon or irritable bowel Application of PCT/US2012/027287, filed on Mar. 1, 2012 syndrome, which are motility disorders of the gastrointes which claims the benefit of and priority to U.S. Provisional tinal tract. Gastrointestinal inflammation can be a chronic Application No. 61/447,891 filed on Mar. 1, 2011, the condition. It is estimated that as many as 1,000,000 Ameri contents of each of which are incorporated by reference in 10 cans are afflicted with inflammatory bowel disease, with their entireties. male and female patients appearing to be equally affected. Most cases are diagnosed before age 30, but the disease can INCORPORATION OF SEQUENCE LISTING occur in the sixth, seventh, and later decades of life. The contents of the text file named “40737 15 IBS and chronic idiopathic constipation are pathological 508001.WO ST25.txt”, which was created on Sep. 11, 2012 conditions that can cause a great deal of intestinal discom and is 113 KB in size, are hereby incorporated by reference fort and distress but unlike the inflammatory bowel diseases, in their entirety. IBS does not cause the serious inflammation or changes in bowel tissue and it is not thought to increase the risk of FIELD OF THE INVENTION colorectal cancer. In the past, inflammatory bowel disease, celiac disease, and IBS were regarded as completely sepa The present invention relates to processes of preparing rate disorders. Now, with the description of inflammation, guanylate cyclase C peptide agonists useful for the treatment albeit low-grade, in IBS, and of symptom overlap between and prevention of various diseases and disorders. IBS and celiac disease, this contention has come under 25 question. Acute bacterial gastroenteritis is the strongest risk BACKGROUND OF THE INVENTION factor identified to date for the subsequent development of postinfective irritable bowel syndrome. Clinical risk factors Guanylate cyclase C is a transmembrane form of gua include prolonged acute illness and the absence of Vomiting. nylate cyclase that is expressed on various cells, including A genetically determined Susceptibility to inflammatory gastrointestinal epithelial cells (reviewed in Vaandrager 30 stimuli may also be a risk factor for irritable bowel syn 2002 Mol. Cell. Biochem. 230:73-83). It was originally drome. The underlying pathophysiology indicates increased discovered as the intestinal receptor for the heat-stable toxin intestinal permeability and low-grade inflammation, as well (ST) peptides secreted by enteric bacteria and which cause as altered motility and visceral sensitivity. Serotonin (5-hy diarrhea. The ST peptides share a similar primary amino acid droxytryptamine 5-HT) is a key modulator of gut function structure with two peptides isolated from intestinal mucosa 35 and is known to play a major role in pathophysiology of IBS. and urine, guanylin and uroguanylin (Currie, et al., Proc. The activity of 5-HT is regulated by c0MP. Nat'l Acad. Sci. USA 89:947-951 (1992); Hamra, et al., While the precise causes of IBS and inflammatory bowel Proc. Nat'l Acad. Sci. USA 90:10464-10468 (1993); Forte, diseases (IBD) are not known, a disruption in the process of L., Reg. Pept. 81:25-39 (1999); Schulz, et al., Cell 63:941 continual renewal of the gastrointestinal mucosa may con 948 (1990); Guba, et al., Gastroenterology 1 11:1558-1568 40 tribute to disease pathology in IBD and aggravate IBS. The (1996); Joo, et al., Am. J. Physiol. 274:G633-G644 (1998)). renewal process of the gastrointestinal lining is an efficient In the intestines, guanylin and uroguanylin act as regula and dynamic process involving the continual proliferation tors of fluid and electrolyte balance. In response to high oral and replenishment of unwanted damaged cells. Proliferation salt intake, these peptides are released into the intestinal rates of cells lining the gastrointestinal mucosa are very lumen where they bind to guanylate cyclase C localized on 45 high, second only to the hematopoietic system. Gastrointes the luminal membrane of enterocytes (simple columnar tinal homeostasis depends on both the proliferation and epithelial cells of the small intestines and colon). The programmed cellular death (apoptosis) of epithelial cells binding of the guanylin peptides to guanylate cyclase C lining the gut mucosa. Cells are continually lost from the induces electrolyte and water excretion into the intestinal Villus into the lumen of the gut and are replenished at a lumen via a complex intracellular signaling cascade that is 50 substantially equal rate by the proliferation of cells in the initiated by an increase in cyclic guanosine monophosphate crypts, followed by their upward movement to the villus.
Load more

Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • Connecticut Medicaid
    ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN
    [Show full text]
  • Advice for Patients Who Take Replacement Steroids (Hydrocortisone, Prednisolone, Dexamethasone Or Plenadren) for Pituitary/Adrenal Insufficiency
    Advice for patients who take replacement steroids (hydrocortisone, prednisolone, dexamethasone or plenadren) for pituitary/adrenal insufficiency A number of you have been in touch looking for advice relating to the global coronavirus (also known as COVID-19) outbreak. If you are on steroid replacement therapy for pituitary or adrenal disease, or care for someone who is, and you’re worried about coronavirus, we’ve brought together a number of resources that we hope you will find useful. Coronavirus Adrenal Insufficiency Advice for Patients Primary adrenal insufficiency refers to all patients with loss of function of the adrenal itself, mostly either due to autoimmune Addison’s disease, or other causes such as congenital adrenal hyperplasia, bilateral adrenalectomy and adrenoleukodystrophy. The overwhelming majority of primary adrenal insufficiency patients suffer from both glucocorticoid and mineralocorticoid deficiency and usually take hydrocortisone (or prednisolone) and fludrocortisone. Our guidance similarly applies to patients with secondary adrenal insufficiency mostly due to pituitary tumours or previous high-dose glucocorticoid treatment. These patients take hydrocortisone for glucocorticoid deficiency As you will be aware it is important for patients with adrenal insufficiency to increase their steroids if unwell as per the usual sick day rules. Please ensure you have sufficient supplies to cover increased doses if you become unwell and an up to date emergency injection of hydrocortisone 100mg. Patients who suffer from a suspected or confirmed infection with coronavirus usually have high fever for many hours of the day, which results in the need for larger than usual steroid doses, so we advise slightly different sick day rules, which are listed below.
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]